423 related articles for article (PubMed ID: 28485312)
1. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
[TBL] [Abstract][Full Text] [Related]
2. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
3. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
Chytra I; Stepan M; Benes J; Pelnar P; Zidkova A; Bergerova T; Pradl R; Kasal E
Crit Care; 2012 Jun; 16(3):R113. PubMed ID: 22742765
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
[TBL] [Abstract][Full Text] [Related]
6. Continuous infusion versus intermittent administration of meropenem in critically ill patients.
Thalhammer F; Traunmüller F; El Menyawi I; Frass M; Hollenstein UM; Locker GJ; Stoiser B; Staudinger T; Thalhammer-Scherrer R; Burgmann H
J Antimicrob Chemother; 1999 Apr; 43(4):523-7. PubMed ID: 10350382
[TBL] [Abstract][Full Text] [Related]
7. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients.
Ahmed N; Jen SP; Altshuler D; Papadopoulos J; Pham VP; Dubrovskaya Y
J Intensive Care Med; 2020 Aug; 35(8):763-771. PubMed ID: 29954243
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Lipman J
Clin Infect Dis; 2013 Jan; 56(2):236-44. PubMed ID: 23074313
[TBL] [Abstract][Full Text] [Related]
10. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
[TBL] [Abstract][Full Text] [Related]
11. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
Brunkhorst FM; Oppert M; Marx G; Bloos F; Ludewig K; Putensen C; Nierhaus A; Jaschinski U; Meier-Hellmann A; Weyland A; Gründling M; Moerer O; Riessen R; Seibel A; Ragaller M; Büchler MW; John S; Bach F; Spies C; Reill L; Fritz H; Kiehntopf M; Kuhnt E; Bogatsch H; Engel C; Loeffler M; Kollef MH; Reinhart K; Welte T;
JAMA; 2012 Jun; 307(22):2390-9. PubMed ID: 22692171
[TBL] [Abstract][Full Text] [Related]
12. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.
Monti G; Bradic N; Marzaroli M; Konkayev A; Fominskiy E; Kotani Y; Likhvantsev VV; Momesso E; Nogtev P; Lobreglio R; Redkin I; Toffoletto F; Bruni A; Baiardo Redaelli M; D'Andrea N; Paternoster G; Scandroglio AM; Gallicchio F; Ballestra M; Calabrò MG; Cotoia A; Perone R; Cuffaro R; Montrucchio G; Pota V; Ananiadou S; Lembo R; Musu M; Rauch S; Galbiati C; Pinelli F; Pasin L; Guarracino F; Santarpino G; Agrò FE; Bove T; Corradi F; Forfori F; Longhini F; Cecconi M; Landoni G; Bellomo R; Zangrillo A;
JAMA; 2023 Jul; 330(2):141-151. PubMed ID: 37326473
[TBL] [Abstract][Full Text] [Related]
13. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML
Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.
Langgartner J; Vasold A; Glück T; Reng M; Kees F
Intensive Care Med; 2008 Jun; 34(6):1091-6. PubMed ID: 18297267
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of meropenem in critically ill patients with severe infections.
Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
[TBL] [Abstract][Full Text] [Related]
17. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
[TBL] [Abstract][Full Text] [Related]
18. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study.
Eisert A; Lanckohr C; Frey J; Frey O; Wicha SG; Horn D; Ellger B; Schuerholz T; Marx G; Simon TP
Int J Antimicrob Agents; 2021 Mar; 57(3):106289. PubMed ID: 33515688
[TBL] [Abstract][Full Text] [Related]
20. Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality.
Garnacho-Montero J; Gutiérrez-Pizarraya A; Escoresca-Ortega A; Fernández-Delgado E; López-Sánchez JM
Crit Care; 2015 Aug; 19(1):302. PubMed ID: 26307060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]